跳至主要内容
临床试验/NCT03960957
NCT03960957已完成3 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines

Galderma R&D12 个研究点 分布在 1 个国家目标入组 301 人开始时间: 2019年6月17日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Galderma R&D
入组人数
301
试验地点
12
主要终点
Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo

研究概览

简要总结

An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Moderate to severe glabellar lines at maximum frown
  • Understands the study requirements and signs an informed consent form

排除标准

  • Botulinum toxin treatment in the face within 6 months prior to study treatment

结局指标

主要结局

Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo

时间窗: Month 1 after treatment

Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)

次要结局

未报告次要终点

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验

Efficacy and Safety of a New Dilution and Injection... | 临床试验